Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial
BMC Nephrology, 06/29/2012

Bleskestad IH et al. – In this crossover trial with alphacalcidol and sevelamer carbonate in patients with chronic kidney disease stage 3b, the levels of intact FGF23 (iFGF23) were not significantly different after the two treatments. However, in the group of patients initiating therapy with sevelamer carbonate the iFGF23 levels seemed to increase while this response was mitigated in the group of patients given alphacalcidol followed by sevelamer carbonate. This may have therapeutic implications on choice of first line therapy. The number of patients is small and this conclusion is in part based on subgroup analysis.